
简介:
- 作者: Chao Ding, Fukang Liu, Huayue Shi, Jing Zuo, Lei Bi, Longgang Shao, Yanqiu Pan
- 杂志: PeerJ
- Doi: https://www.doi.org/10.7717/peerj.19568
- 出版日期: 2025-06-24
摘要
Background: Recurrent spontaneous abortion (RSA) affects 1–5% of pregnant women; however, the mechanisms underlying this condition remain unknown. Dysangiogenesis in the placenta is an essential factor in the pathogenesis of RSA. Studies have verified that microRNAs (miRNAs) are vital for RSA; however, their mechanism of action in regulating angiogenesis remains unclear. Therefore, we explored the contribution of key miRNAs that regulate angiogenesis in RSA.
Methods: The abortion mouse model was constructed by intraperitoneal injection of beta2-Glycoprotein I (β2-GPI). The abnormal expression of miRNAs in the placenta of the abortion mice was screened using miRNA-seq. Based on miRNA databases, miR-381-3p, which is highly expressed in abortion mice, may bind to vascular endothelial growth factor A (VEGFA). Subsequently, we investigated the effects of the miR-381-3p/VEGFA axis on the angiogenesis of vascular endothelial cells using real-time quantitative polymerase chain reaction, Transwell, wound healing, tube formation, western blotting, and dual-luciferase reporter system. Furthermore, an in vivo experiment was used to confirm miR-381-3p knockdown contribution in the abortion mouse model.
Results: miR-381-3p overexpression inhibited the migration and angiogenesis of C166 cells (a mouse vascular endothelial cell line), whereas miR-381-3p knockdown had the opposite effect. The dual-luciferase reporter system revealed that miR-381-3p bound to the VEGFA 3′ UTR, and VEGFA knockdown counteracted the beneficial effect of the miR-381-3p inhibitor on angiogenesis. An in vivo study demonstrated that miR-381-3p knockdown may reduce inflammation and damage to the placenta and fetus during abortion by activating the VEGFA/nuclear factor kappa B (NF-κB) pathway.
Conclusion: miR-381-3p may cause insufficient placental blood flow by inhibiting the VEGFA pathway and can be used as a potential therapeutic target for RSA.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
